D-0344-2019 Class III Terminated

Recalled by Amerigen Pharmaceuticals Inc. — Lyndhurst, NJ

FDA drug recall D-0344-2019 was initiated by Amerigen Pharmaceuticals Inc. on Dec 20, 2018 and is designated Class III. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Dec 17, 2019). Affected quantity: 3552 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 2, 2019
Initiation Date
Dec 20, 2018
Termination Date
Dec 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3552 bottles

Product description

Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count (NDC 43975-253-14) bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Product was distributed to 4 wholesalers and 2 retail accounts who may have further distributed the products.

Code information

a) Lot # 18B005 A and b) Lot # 18B005 B, exp 02/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0344-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0344-2019. Report a data issue: hello@regdatalab.com.